meglimid 1 mg tabletes
krka, d.d., novo mesto, slovenia - glimepirīds - tabletes - 1 mg
meglimid 4 mg tabletes
krka, d.d., novo mesto, slovenia - glimepirīds - tablete - 4 mg
imatinib sandoz 400 mg apvalkotās tabletes
sandoz d.d., slovenia - imatinibs - apvalkotā tablete - 400 mg
imatinib sandoz 100 mg apvalkotās tabletes
sandoz d.d., slovenia - imatinibs - apvalkotā tablete - 100 mg
irinotecan ebewe 20 mg/ml koncentrāts infūziju šķīduma pagatavošanai
sandoz d.d., slovenia - irinotekāna hidrohlorīda trihidrāts - koncentrāts infūziju šķīduma pagatavošanai - 20 mg/ml
torendo q-tab 2 mg mutē disperģējamās tabletes
krka, d.d., novo mesto, slovenia - risperidons - mutē disperģējamās tabletes - 2 mg
torendo q-tab 1 mg mutē disperģējamās tabletes
krka, d.d., novo mesto, slovenia - risperidons - mutē disperģējamās tabletes - 1 mg
bimatoprost/timolol sandoz 0,3 mg/5 mg/ml acu pilieni, šķīdums
sandoz d.d., slovenia - bimatoprostum, timololum - acu pilieni, šķīdums - 0,3 mg/5 mg/ml
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
ciprinol 2 mg/ml šķīdums infūzijām
krka, d.d., novo mesto, slovenia - ciprofloksacīns - Šķīdums infūzijām - 400 mg/200 ml